Quick Answer
Akari Therapeutics Plc reported Cash and Equivalents of $2.60 million for fiscal year 2024.
Akari Therapeutics Plc Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $2.60M | -32.4% |
| 2023 | $3.85M | -71.0% |
| 2022 | $13.25M | +41.5% |
| 2021 | $9.36M | -33.4% |
| 2020 | $14.06M | +14.1% |
| 2020 | $12.32M | -3.4% |
| 2020 | $12.75M | +63.0% |
| 2020 | $7.82M | +36.5% |
| 2019 | $5.73M | -8.6% |
| 2019 | $6.27M | +129.1% |
| 2019 | $2.74M | -55.5% |
| 2019 | $6.15M | +12.8% |
| 2018 | $5.45M | -80.6% |
| 2017 | $28.11M | -17.6% |
| 2016 | $34.10M | -50.5% |
| 2015 | $68.92M | +1971.2% |
| 2014 | $3.33M | +501.0% |
| 2013 | $553.7K | -49.9% |
| 2012 | $1.10M | +18300.0% |
| 2011 | $6.0K | -33.3% |
| 2010 | $9.0K | — |
| 2004 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $2.71M | -35.1% | +5.0% |
| March 31, 2025 | $2.58M | +97.1% | -0.7% |
| December 31, 2024 | $2.60M | -32.4% | +15.7% |
| September 30, 2024 | $2.25M | — | -46.2% |
| June 30, 2024 | $4.18M | — | +218.9% |
| March 31, 2024 | $1.31M | — | -65.9% |
| December 31, 2023 | $3.85M | — | -93.7% |
| March 31, 2016 | $61.43M | +4523.4% | -10.9% |
- Akari Therapeutics Plc showed a decrease of -32.4% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from Akari Therapeutics Plc’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: